<DOC>
	<DOCNO>NCT00216060</DOCNO>
	<brief_summary>Risedronate orally administer pyridinyl bisphosphonate 36 time potent pamidronate 72 time potent clodronate . Four randomized , double-blind trial carry patient postmenopausal osteoporosis . In 2 study , vertebral fracture incidence reduce daily dose 5 mg risedronate 65 % 49 % relative placebo 1 3 year , respectively . In trial , risedronate improve lumbar spine , femoral neck , femoral trochanter bone mineral density ( BMD ) 6 month . In addition , preclinical study show risedronate potent pamidronate clodronate inhibit adhesion prostate cancer cell bone prevent tumor cell invasion . The incidence osteoporosis prostate cancer patient well establish ; therefore , advantageous ass efficacy oral bisphosphonate therapy .</brief_summary>
	<brief_title>Risedronate Prevent Skeletal Related Events Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy</brief_title>
	<detailed_description>OUTLINE : This randomize , placebo-controlled , double-blind , multicenter , 2 arm study . The study population consist prostate cancer patient metastatic bone disease androgen-deprivation therapy plan . After stratification base patient 's age , performance status , severity metastatic disease , patient randomize 1:1 ratio follow treatment arm : - Daily oral risedronate combine androgen deprivation - Daily oral placebo combine androgen deprivation Initial clinical evaluation perform 2-week screening period . While patient receive per-protocol treatment , study assessment perform every 4 week first 3 month , every 12 week thereafter . Performance Status : Eastern Cooperative Oncology Group ( ECOG ) 0 2 Life Expectancy : At least 12 week Hematopoietic : - Absolute neutrophil count ( ANC ) &gt; 1,000/mm3 - Platelet count &gt; 100,000/mm3 - international normalized ratio ( INR ) &lt; 1.5 x upper limit normal unless therapeutic anticoagulation - Partial thromboplastin time ( PTT ) &lt; 1.5 x upper limit normal unless therapeutic anticoagulation Hepatic : - Bilirubin &lt; 1.5 mg/dL - Alanine transaminase ( ALT ) &lt; 2.5 x upper limit normal Renal : - Creatinine clearance &gt; 30 mL/min ( Cockcroft-Gault ) Cardiovascular : - No significant history uncontrolled cardiac disease ( i.e. , uncontrolled hypertension , unstable angina , congestive heart failure ) . Pulmonary : - Not specify Calcium : - Corrected serum calcium = ( 4.0 g/dL - actual albumin g/dL ) x 0.8 + serum calcium</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Risedronate Sodium</mesh_term>
	<mesh_term>Etidronic Acid</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma prostate metastatic bone disease ( CT , MRI bone scan ) plan start &lt; 30 day begin androgen deprivation therapy . Patients lymph node visceral metastasis eligible Patients may receive palliative radiation therapy investigator discretion first 4 week begin protocol therapy . No neuroendocrine , small cell transitional cell cancer prostate No abnormal bone metabolism ( i.e. , Paget 's disease , untreated hyperthyroidism , untreated hyperprolactinemia , untreated Cushing 's disease ) . No use calcitonin within 14 day register protocol therapy previous use bisphosphonates . No major surgery within 4 week registration protocol therapy . No adjuvant chemotherapy within 6 month registration protocol therapy . No previous chemotherapy metastatic disease . No hormonal therapy adjuvant set within 12 month registration protocol therapy ; previous hormonal therapy must exceed 6 month . No prior history malignancy past 5 year exception basal cell squamous cell carcinoma skin . No history allergy drug reaction bisphosphonates .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>